首页> 外文期刊>Veins and Lymphatics >Timing and modality of the sclerosing agents binding to the human proteins: laboratory analysis and clinical evidences
【24h】

Timing and modality of the sclerosing agents binding to the human proteins: laboratory analysis and clinical evidences

机译:硬化剂与人蛋白结合的时间和方式:实验室分析和临床证据

获取原文
           

摘要

Sclerosing agents (SA) are blood inactivated. Nevertheless, investigations concerning the interaction among SA and blood components have never been deeply investigated. Aim of the study is to precisely identify SA blood ligands, to determine their binding time and to highlight the clinical consequences. Thirty-one blood samples were collected from chronic venous disease patients and tested by capillary and agarose gel (AGE) electrophoresis before and after adding polidocanol (POL) and sodiumtetradecylsulphate (STS). The two different types of electrophoresis allowed an evaluation of the blood proteins binding with the sclerosing agents, with a reaction time lower than 8 seconds for the AGE. Subsequently six patients underwent foam sclerotherapy and then were subdivided in group A (4 patients) and B (2 patients). In group A blood sample was obtained from the ipsilateral brachial vein immediately before (T0) and repeated 1, 3, 5, and 10 minutes after injection of STS 3% injection into the GSV. In group B, the same procedure was performed with the same timing from the ipsilateral femoral vein. Free STS (fSTS) and total proteinbound STS (bSTS) were measured. POL mainly binds to β-globulins (11%), while STS to albumin and α-globulins (62.6% and 30.7%) on the protidogram, respectively. Both in the brachial and in the femoral vein, the average fSTS was always 0. STS binds to albumin (62.6%) and α-globulins (30.7%), while POL is bound mainly by the b-globulins (11%). The present paper demonstrates how the vast majority of the sclerosing agent is bound to the blood proteins, suggesting the need to look for possible sclerotherapy complications factors also in the used gas and/or in the subsequent cathabolites release.
机译:硬化剂(SA)被血液灭活。然而,关于SA与血液成分之间相互作用的研究从未深入研究过。该研究的目的是精确鉴定SA血液配体,确定其结合时间并突出临床后果。从慢性静脉疾病患者中收集了31个血液样本,并在加入多多酚醇(POL)和十四烷基硫酸钠(STS)之前和之后通过毛细管和琼脂糖凝胶(AGE)电泳进行了测试。两种不同类型的电泳可以评估与硬化剂结合的血液蛋白,AGE的反应时间低于8秒。随后,六名患者接受了泡沫硬化疗法,然后分为A组(4例)和B组(2例)。在A组中,在即将(T0)之前从同侧肱静脉中获得血液样品,并在将STS注射3%到GSV中之后重复1、3、5和10分钟。在B组中,从同侧股静脉以相同的时间进行相同的程序。测量游离STS(fSTS)和总蛋白结合STS(bSTS)。 POL主要结合β-球蛋白(11%),而STS分别结合白蛋白和α-球蛋白(62.6%和30.7%)。在臂和股静脉中,平均fSTS始终为0。STS与白蛋白(62.6%)和α-球蛋白(30.7%)结合,而POL主要由b-球蛋白(11%)结合。本文证明了绝大多数的硬化剂如何与血液蛋白结合,表明需要在使用的气体和/或随后的分解代谢物中寻找可能的硬化疗法并发症因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号